NEW YORK (GenomeWeb) – Proteomics firm Biognosys said this week that it has licensed a patent from the Swiss Federal Institute of Technology Zurich covering a technology for capture of N-glycans.

The company said that it plans to use the technology to offer glycol-protein profiling as part of its high-resolution mass spec-based targeted quantitation offerings.

Developed by ETH Zurich research Ruedi Aebersold and colleagues at the Institute for Systems Biology in Seattle, the technique enables enrichment of N-glycosylated proteins.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.